Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Método para predecir la resistencia al tratamiento con clopidogrel

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20160128002
Publicado:
10/02/2016
Caducidad:
10/02/2017
Resumen:
Dos centros de investigación catalanes han desarrollado un método para predecir la resistencia al tratamiento con clopidogrel en pacientes que han sufrido un evento aterosclerótico. Esta tecnología permite mejorar el programa de tratamiento personalizado del paciente. Se buscan compañías farmacéuticas y biotecnológicas especializadas en enfermedades cardiovasculares con el fin de establecer acuerdos de licencia para desarrollar un kit comercial.

Details

Tittle:
Method for predicting resistance to clopidogrel treatment
Summary:
Two Catalan research centres have developed a method to predict resistance to clopidogrel treatment in patients after an athero-sclerotic event. With this technology it is possible to improve the personalized treatment plan for the patient.
The groups are looking for pharmaceutical or biotechnological companies specialising in cardiovascular diseases for license agreement to develop a commercial kit.
Description:
Clopidogrel is an oral, thienopyridine-class antiplatelet agent used to inhibit blood clots to reduce various atherosclerotic events like myocardial infarction, ictus and artery disease, or in the prevention of thrombosis in intracoronary stenting treatment.
Approximately 30% of patients having suffered from ictus receive treatment with clopidgrel. It is estimated that approximately 35% of patients treated with this drug do not respond to the treatment.
In addition, 2% of the treated population may have haemorrhage as secondary effect of the clopidogrel treatment.

Two Catalan hospital-based research centers have developed a predictive method to determine the probability of successful clopidogrel treatment based on a biomarker. It is about a polymorphism located in a SNP at a specific gene locus.
With this method, it is possible to improve a personalized therapeutic plan for patients after an atherosclerotic event.

The research groups are looking for companies for license agreement to develop a prediction kit related to the resistance to clopidogrel, either sole or in combination with other biomarkers.
Advantages and Innovations:
The genetic biomarker is associated directly with 5 times more risk of a new cardiovascular event taking account the resistance to clopidogrel (affecting 35% of patients). Thanks to this biomarker, doctors can identify patients with high risk of suffering a new cardiovascular event, in contrast to current genetic biomarkers that focus on platelet activity.
Stage of Development:
Concept stage
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT patent application (November 2015).

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: Pharmaceutical and biotech companies

- Specific area of activity of the partner: Cardiovascular diseases

- Task to be performed by the partner sought: To develop the commercial kit

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German
Spanish

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis
06001011 Enfermedades circulatorias y del corazón
06002007 Ensayos in vitro, experimentos
06003002 Expresión genética, investigación proteómica